Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for pain and inflammatory marker reduction after neurosurgery
IRCT20160709028845N2Phase 3Completed
- Sponsor
- Abadan University of Medical Sciences
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of dexmedetomidine in postoperative pain and Systemic Inflammatory Response Syndrome (SIRS) (2 arms), sponsored by Abadan University of Medical Sciences. Primary endpoints: Change in interleukin-6 level, Change in tumor necrosis factor-alpha level and 2 more. Started Nov 2025; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
postoperative painSystemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on IRCT20160709028845N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160709028845N2.